Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company focused on hepatitis B virus (HBV) therapies, announced that CEO John McHutchison will present at the HC Wainwright Virtual BIOCONNECT Conference from January 10-13, 2022. The presentation will be available for on-demand viewing starting January 10, 2022, at 7:00 a.m. EST on the company's website. Assembly Bio aims to develop curative therapies for the 270 million people worldwide living with HBV, leveraging its innovative oral core inhibitors and combination studies.
- CEO John McHutchison will present at the HC Wainwright Virtual BIOCONNECT Conference, potentially increasing visibility and investor interest.
- Assembly Bio's focus on curative therapies for HBV targets a significant global health issue affecting 270 million people.
- The company faces inherent risks and uncertainties in clinical study timelines and outcomes.
- Assembly Bio's ongoing development is contingent on successful collaborations and maintaining financial resources.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John McHutchison, AO, MD, chief executive officer and president, will present during the HC Wainwright Virtual BIOCONNECT Conference, January 10-13, 2022.
The presentation will be available for on-demand viewing beginning Monday, January 10, 2022 at 7:00 a.m. EST in the Events and Presentations section of the Company’s website at www.assemblybio.com.
About Assembly Biosciences
Assembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies for HBV cure and research programs focused on the discovery of additional novel antiviral mechanisms for HBV, and other viral diseases. For more information, visit assemblybio.com.
Forward-Looking Statements
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s clinical collaboration agreements, in the currently anticipated timeframes; safety and efficacy data from clinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; continued development and commercialization of Assembly Bio’s HBV product candidates, if successful, in the China territory will be dependent on, and subject to, Assembly Bio’s collaboration agreement governing its HBV-related activity in the China territory; Assembly Bio’s ability to maintain financial resources necessary to continue its clinical studies and fund business operations; any impact that the COVID-19 pandemic may have on Assembly Bio’s business and operations, including initiation, enrollment and continuation of its clinical studies or timing of discussions with regulatory authorities; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor and Corporate:
Lauren Glaser
Senior Vice President, Investor Relations and Corporate Affairs
(415) 521-3828
lglaser@assemblybio.com
Media:
Sam Brown Inc.
Audra Friis
(917) 519-9577
ASMBMedia@sambrown.com
FAQ
When is Assembly Biosciences presenting at the HC Wainwright Virtual BIOCONNECT Conference?
How can I view Assembly Biosciences' presentation at the conference?
What is Assembly Biosciences' focus in biotechnology?
What is the significance of Assembly Biosciences' therapies?
